Open-market purchases of Xenon Pharmaceuticals Inc. (XENE) stock by its own executives, directors and 10% owners — every Form 4 buy of $250K or more that SPX Lens's daily insider scan has recorded, newest first.
| Scan | Insider | Value | Type | |||
|---|---|---|---|---|---|---|
| Oct 2, 2026 | Ian MortimerPresident & CEO | $1.12M | Added | |||
| Cluster buy with CFO same day (Sept 30) after clinical trial pause drove stock lower; avg $37.38; now $38.93 (+4.1%). Stock up 5.2% on the day of disclosure. | ||||||
| Oct 2, 2026 | Thomas Patrick KellyChief Financial Officer | $560K | New stake | |||
| New position; CFO buys alongside CEO on same day (Sept 30) after clinical trial pause selloff; avg $37.32; now $38.93 (+4.3%). First reported direct holding. | ||||||
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.
Open the live chartOpen in the Stocks tab© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.